by Boston Scientific as the PROMUS Stent, versus the TAXUS Express2 Paclitaxel-Eluting Coronary Stent System in the treatment of coronary artery disease. The Company plans to issue a press release at this time. Wednesday, May 23 * Focus Session on DES in diabetics(1). The Company will sponsor a focus session entitled "Optimizing coronary drug-eluting stent results in diabetics," chaired by Prof. Sigmund Silber, M.D., from 2:00 - 4:30 p.m. in Room 9. In addition to a live case transmission, experts will review practical techniques and strategies for dealing with PCI in diabetic patients. (1) The safety and effectiveness of the TAXUS Express(TM) Stent have not been established in patients with diabetes. Thursday, May 24 * Focus Session on carotid artery stenting. The Company will sponsor a focus session entitled "Clinical and technical considerations for daily carotid artery stenting practice," chaired by Nick Hopkins, M.D., from 2:00 - 4:30 p.m. in Room 6. In addition to a live case transmission, experts will review key clinical data and technology selection criteria as well as basic neurorescue techniques. * Analyst Meeting. From 9:00-10:00 a.m., the Company will host an analyst meeting at the Hotel Hilton Diagonal Mar. The meeting is open to the media. Registration is required for admittance. This meeting is being webcast and can be accessed at Boston Scientific's website, www.bostonscientific.com. Please visit the website for details on how to access the webcast. A replay of the webcast will be archived and available in the Webcast and Archives section of the Investor Relations site at www.bostonscientific.com.